To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure such is the case), the information contained in this document for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. The directors of Horizon accept responsibility for the information contained in this document. Statement Required by the Irish Takeover Rules We believe science and compassion must work together to transform lives.
Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. Horizon Therapeutics plc is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. The Company confirms that as of June 9, 2023, there were outstanding options to purchase up to 4,602,001 Ordinary Shares and outstanding restricted stock units and performance stock units conferring on their holders vested or unvested rights to convert into, or receive, up to an aggregate of 1,810,200 Ordinary Shares and incremental restricted stock units to be issued of 4,124,381 Ordinary Shares. The International Securities Identification Number for these securities is IE00BQPVQZ61. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol 'HZNP'. The Company has 384,366 Ordinary Shares which are held as treasury shares. DUBLIN - In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the 'Irish Takeover Rules'), Horizon confirms that, as of the close of business on June 9, 2023, Horizon's issued ordinary share capital is comprised of 228,928,661 ordinary shares, nominal value $0.0001 per share and 40,000 deferred ordinary shares of EUR1.00 each.
0 kommentar(er)
